- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05327114
Effekt- og sikkerhedsundersøgelse af Nipocalimab til voksne med kronisk inflammatorisk demyeliniserende polyneuropati (CIDP)
Fase 2/3, flertrins-, multicenter-, randomiseret, dobbeltblindet, placebokontrolleret parallelgruppetilbagetrækningsundersøgelse for at evaluere effektiviteten og sikkerheden af Nipocalimab administreret til voksne med kronisk inflammatorisk demyeliniserende polyneuropati (CIDP)
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.
Studieoversigt
Status
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
- Fase 3
Udvidet adgang
Kontakter og lokationer
Studiekontakt
- Navn: Study Contact
- Telefonnummer: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Studiesteder
-
-
-
Buenos Aires, Argentina, C1199ABB
- Aktiv, ikke rekrutterende
- Hospital Italiano de Buenos Aires
-
Buenos Aires, Argentina, C1428AQK
- Rekruttering
- Instituto Fleni
-
Buenos Aires, Argentina, C1428
- Afsluttet
- Hospital Gral Agudos Ignacio Pirovano
-
Rosario, Argentina, 2900
- Rekruttering
- INECO Neurociencias Orono
-
-
-
-
-
Melbourne, Australien, 3004
- Afsluttet
- The Alfred Hospital
-
Parkwood, Australien, 4215
- Afsluttet
- Gold Coast University Hospital
-
-
-
-
-
Ottawa, Canada, K1N 6N5
- Rekruttering
- The Ottawa Hospital Ottawa NeuroMuscular Centre
-
-
-
-
-
Floridablanca, Colombia, 681004
- Afsluttet
- Fundación Cardiovascular de Colombia - Instituto del Corazón Floridablanca
-
Medellín, Colombia, 50021
- Aktiv, ikke rekrutterende
- Instituto Neurológico de Colombia
-
-
-
-
-
Birmingham, Det Forenede Kongerige, B15 2TH
- Afsluttet
- University Hospitals Birmingham NHS Foundation Trust
-
Devon, Det Forenede Kongerige, EX2 5DW
- Afsluttet
- Royal Devon & Exeter Hospital
-
Glasgow, Det Forenede Kongerige, G514TF
- Aktiv, ikke rekrutterende
- NHS Greater Glasgow and Clyde
-
London, Det Forenede Kongerige, NW3 2QG
- Afsluttet
- Royal Free Hospital
-
Sheffield, Det Forenede Kongerige, S10 2 JF
- Aktiv, ikke rekrutterende
- Sheffield Teaching Hospitals NHS Foundation Trust
-
-
-
-
Colorado
-
Centennial, Colorado, Forenede Stater, 80112
- Aktiv, ikke rekrutterende
- IMMUNOe Health and Research Centers
-
-
Florida
-
Coral Springs, Florida, Forenede Stater, 33067
- Afsluttet
- Healthcare Innovations Institute Inc
-
Maitland, Florida, Forenede Stater, 32751
- Afsluttet
- Neurology Associates PA
-
Miami, Florida, Forenede Stater, 33136
- Aktiv, ikke rekrutterende
- ALS Center at the University of Miami
-
-
Georgia
-
Augusta, Georgia, Forenede Stater, 30912
- Afsluttet
- Augusta University
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66160
- Afsluttet
- University of Kansas Medical Center
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21287
- Afsluttet
- Johns Hopkins Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02111
- Afsluttet
- Boston Clinical Trials
-
-
Michigan
-
Royal Oak, Michigan, Forenede Stater, 48073
- Afsluttet
- Beaumont Hospital Royal Oak
-
-
Missouri
-
Kansas City, Missouri, Forenede Stater, 64128
- Afsluttet
- Kansas City Veterans Affairs Medical Center
-
-
New York
-
New York, New York, Forenede Stater, 10032
- Afsluttet
- The Neurological Institute of New York
-
Patchogue, New York, Forenede Stater, 11772
- Afsluttet
- South Shore Neurologic Associates - Patchogue
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater, 28204
- Afsluttet
- The Neurological Institute, PA
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44195
- Aktiv, ikke rekrutterende
- Cleveland Clinic Main Campus
-
-
Texas
-
Austin, Texas, Forenede Stater, 78756
- Afsluttet
- Austin Neuromuscular Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53215
- Aktiv, ikke rekrutterende
- Advocate Health - Aurora St. Luke's Medical Center
-
-
-
-
-
Bordeaux, Frankrig, 33000
- Afsluttet
- CHU Bordeaux
-
Bron, Frankrig, 69699
- Afsluttet
- Hospices Civils de Lyon HCL
-
Le Kremlin-Bicêtre, Frankrig, 94270
- Aktiv, ikke rekrutterende
- Hopital de Bicetre
-
Marseille, Frankrig, 13385
- Aktiv, ikke rekrutterende
- Hopital de la Timone
-
Nice, Frankrig, 06000
- Aktiv, ikke rekrutterende
- Hopital PASTEUR
-
Nîmes, Frankrig, 30029
- Aktiv, ikke rekrutterende
- CHU Nimes Hopital Caremeau
-
Paris, Frankrig, 75013
- Afsluttet
- Hopital de la Pitie Salpetriere
-
Paris, Frankrig, 75019
- Afsluttet
- Fondation Adolphe de Rothschild Hospital
-
Strasbourg, Frankrig, 67200
- Aktiv, ikke rekrutterende
- CHRU Strasbourg
-
-
-
-
-
Athens, Grækenland, 12462
- Rekruttering
- Attikon General Hospital of Athens
-
Athens, Grækenland, 11527
- Afsluttet
- Papageorgiou General Hospital Of Thessaloniki
-
Pátrai, Grækenland, 26504
- Afsluttet
- Patras University Hospital
-
Thessaloniki, Grækenland, 54636
- Rekruttering
- Ahepa Hospital Aristotle University of Thessaloniki
-
-
-
-
-
Catania, Italien, 95123
- Afsluttet
- Azienda Ospedaliero-Universitaria Policlinico di Catania
-
Genova, Italien, 16132
- Afsluttet
- Azienda Ospedaliera Universitaria San Martino di Genova
-
Milan, Italien, 20144
- Afsluttet
- Casa di Cura del Policlinico
-
Milan, Italien, 20133
- Afsluttet
- Istituto Neurologico Carlo Besta
-
Naples, Italien, 80131
- Aktiv, ikke rekrutterende
- Azienda Ospedaliera di Rilievo Nazionale A Cardarelli
-
Orbassano, Italien, 10043
- Afsluttet
- Aou San Luigi Gonzaga
-
Pavia, Italien, 27100
- Afsluttet
- Fondazione Istituto Neurologico Casimiro Mondino
-
Roma, Italien, 00168
- Afsluttet
- Fondazione Policlinico Universitario A Gemelli IRCCS
-
Rozzano, Italien, 20086
- Afsluttet
- IRCCS Istituto Clinico Humanitas
-
-
-
-
-
Asahikawa, Japan, 070-0901
- Aktiv, ikke rekrutterende
- National Hospital Organization Asahikawa Medical Center
-
Bunkyō City, Japan, 113 8519
- Aktiv, ikke rekrutterende
- Institute of Science Tokyo Hospital
-
Chiba, Japan, 260-8677
- Afsluttet
- Chiba University Hospital
-
Hamamatsu, Japan, 430-8558
- Aktiv, ikke rekrutterende
- Seirei Hamamatsu General Hospital
-
Isehara, Japan, 259-1193
- Aktiv, ikke rekrutterende
- Tokai University Hospital
-
Kobe, Japan, 650 0047
- Afsluttet
- Kobe City Medical Center General Hospital
-
Kodaira-shi, Japan, 187-8551
- Aktiv, ikke rekrutterende
- National Center of Neurology and Psychiatry
-
Koshigaya, Japan, 343-8555
- Aktiv, ikke rekrutterende
- Saitama Medical Center
-
Kumamoto, Japan, 860-8556
- Afsluttet
- Kumamoto University Hospital
-
Nagoya, Japan, 466-8560
- Aktiv, ikke rekrutterende
- Nagoya University Hospital
-
Nagoya, Japan, 455-8530
- Aktiv, ikke rekrutterende
- Chubu Rosai Hospital
-
Osaka Sayama Shi, Japan, 589 8511
- Afsluttet
- Kindai University Hospital
-
Sendai, Japan, 983-8520
- Aktiv, ikke rekrutterende
- National Hospital Organization Sendai Medical Center
-
Shimotsuga Gun, Japan, 321 0293
- Afsluttet
- Dokkyo Medical University Hospital
-
Shinjuku-ku, Japan, 162-8666
- Afsluttet
- Tokyo Women's Medical University Hospital
-
Tenri, Japan, 632-0015
- Afsluttet
- Tenri Hospital
-
Toon-shi, Japan, 791-0295
- Afsluttet
- Ehime University Hospital
-
Toyama, Japan, 930-0194
- Afsluttet
- Toyama University Hospital
-
Ube, Japan, 755-8505
- Afsluttet
- Yamaguchi University Hospital
-
-
-
-
-
Beijing, Kina, 100191
- Afsluttet
- Peking University Third Hospital
-
Beijing, Kina, 100034
- Afsluttet
- Peking University First Hospital
-
Beijing, Kina, 100053
- Aktiv, ikke rekrutterende
- Xuanwu Hospital ,Capital Medical University
-
Beijing, Kina, 100070
- Aktiv, ikke rekrutterende
- Beijing Tiantan Hospital, Capital Medical University
-
Changchun, Kina, 130021
- Aktiv, ikke rekrutterende
- The First Hospital of Jilin University
-
Changsha, Kina, 410008
- Afsluttet
- Xiangya Hospital Central South University
-
Changsha, Kina, 410008
- Aktiv, ikke rekrutterende
- The Third Xiangya Hospital of Central Sourth University
-
Chengdu, Kina, 610072
- Afsluttet
- Sichuan Provincial Peoples Hospital
-
Chifeng, Kina, 024000
- Afsluttet
- Chifeng Municipal Hospital
-
Fuzhou, Kina, 350001
- Aktiv, ikke rekrutterende
- Fujian Medical University Union Hospital
-
Guangzhou, Kina, 510080
- Aktiv, ikke rekrutterende
- The First Affiliated Hospital Sun Yat sen University
-
Jinan, Kina, 250012
- Aktiv, ikke rekrutterende
- Qilu Hospital of Shandong University
-
Jinan, Kina, 250014
- Afsluttet
- Qianfoshan hospital of Shandong Province
-
Nanchang, Kina, 330006
- Aktiv, ikke rekrutterende
- The First Affiliated Hospital of NanChang University
-
Shanghai, Kina, 200336
- Afsluttet
- Tong Ren Hospital Shanghai Jiao Tong University school of medicine
-
Shanghai, Kina, 200040
- Aktiv, ikke rekrutterende
- Huashan Hospital Fudan University
-
Wuhan, Kina, 430023
- Afsluttet
- Renmin Hospital of Wuhan University
-
Xi'an, Kina, 710032
- Afsluttet
- Tangdu hospital the Fourth Military Medical
-
Xi'an, Kina, 710075
- Aktiv, ikke rekrutterende
- Xi 'an GaoXin Hospital
-
-
-
-
-
Monterrey, Mexico, 64710
- Afsluttet
- i Can Oncology Center
-
Tlalnepantla, Mexico, 54055
- Rekruttering
- Clinical Research Institute S.C.
-
-
-
-
-
Chorzów, Polen, 41 500
- Afsluttet
- Centrum Medyczne
-
Krakow, Polen, 30 539
- Afsluttet
- Specjalistyczne Gabinety Lekarskie
-
Lublin, Polen, 20 093
- Afsluttet
- Prywatny Gabinet Lekarski
-
Poznan, Polen, 61 731
- Aktiv, ikke rekrutterende
- Clinical Research Center sp z o o MEDIC R s k
-
-
-
-
-
Almada, Portugal, 2805-267
- Aktiv, ikke rekrutterende
- Hospital Garcia de Orta
-
Braga, Portugal, 4710-243
- Afsluttet
- Hospital de Braga
-
Porto, Portugal, 4200 319
- Aktiv, ikke rekrutterende
- Centro Hospitalar de Sao Joao Epe
-
-
-
-
-
Alicante, Spanien, 03010
- Aktiv, ikke rekrutterende
- Hosp. Gral. Univ. de Alicante
-
Barcelona, Spanien, 8035
- Afsluttet
- Hosp Univ Vall D Hebron
-
Bilbao, Spanien, 48013
- Aktiv, ikke rekrutterende
- Hosp. Univ. de Basurto
-
Donostia / San Sebastian, Spanien, 20014
- Afsluttet
- Hosp. Univ. Donostia
-
Madrid, Spanien, 28040
- Afsluttet
- Hosp. Clinico San Carlos
-
Seville, Spanien, 41009
- Aktiv, ikke rekrutterende
- Hosp. Virgen Macarena
-
-
-
-
-
Seoul, Sydkorea, 05030
- Afsluttet
- Konkuk University Medical Center
-
Seoul, Sydkorea, 02447
- Afsluttet
- Kyunghee University Medical Center
-
Seoul, Sydkorea, 135-710
- Afsluttet
- Samsung Medical Center
-
-
-
-
-
Kaohsiung City, Taiwan, 88301
- Afsluttet
- Kaohsiung Chang Gung Memorial Hospital
-
Taipei, Taiwan, 100
- Aktiv, ikke rekrutterende
- National Taiwan University Hospital
-
Taipei, Taiwan, 111
- Aktiv, ikke rekrutterende
- Shin Kong Wu Ho Su Memorial Hospital
-
-
-
-
-
Hradec Králové, Tjekkiet, 500 05
- Aktiv, ikke rekrutterende
- Fakultni nemocnice Hradec Kralove
-
Ostrava, Tjekkiet, 708 52
- Afsluttet
- Fakultni Nemocnice Ostrava
-
Pardubice, Tjekkiet, 53203
- Afsluttet
- Pardubicka krajska nemocnice a s
-
-
-
-
-
Berlin, Tyskland, 13347
- Aktiv, ikke rekrutterende
- Judisches Krankenhaus Berlin
-
Bochum, Tyskland, 44791
- Afsluttet
- St. Josef-Hospital, Ruhr-Universität Bochum
-
Halle, Tyskland, 6120
- Aktiv, ikke rekrutterende
- Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH
-
Hanover, Tyskland, 30625
- Aktiv, ikke rekrutterende
- Medizinische Hochschule Hannover
-
Leipzig, Tyskland, 4103
- Afsluttet
- Universitaetsklinikum Leipzig
-
Potsdam, Tyskland, 14471
- Afsluttet
- St Josefs Krankenhaus Potsdam Sanssouci
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Adults greater than or equal to (>=) 18 years of age at the time of consent and as applicable, must also meet the legal age of consent in the jurisdiction in which the study is taking place
- Diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) according to criteria of the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) 2021, progressing or relapsing forms. CIDP diagnosis to be adjudicated by independent committee during screening period
- Inflammatory Neuropathy Cause and Treatment (INCAT) disability score between 2 and 9 at the Run-In Baseline visit for participants entering Run-In, or Stage A Baseline visit for participants directly entering Stage A. Participants with an INCAT score of 2 at trial entry must have this score exclusively from the leg disability score
- Fulfilling any of the following treatment conditions: a) Currently treated with oral corticosteroids (CS) less than or equal to (<=) 20 milligrams (mg)/day; or b) Currently treated with pulsed CS, and/or intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) and the participant is willing to discontinue no later than the run-in baseline visit; or c) Currently treated with oral CS greater than (>) 20 mg/day and the participant is willing to taper to <=20 mg/day during the run-in period; or d) Without previous treatment (treatment naive); or treatment with CS and/or IVIg or SCIg discontinued at least 3 months prior to screening (untreated)
- Active disease as determined by CIDP Disease Activity Status (CDAS) score >= 3
- Other protocol-defined inclusion criteria will apply
Exclusion Criteria:
- Has a history of severe and/or uncontrolled hepatic (example, viral/alcoholic/autoimmune hepatitis/cirrhosis and/or metabolic liver disease), gastrointestinal, renal, pulmonary, cardiovascular, psychiatric, neurological or musculoskeletal disorder, hypertension and/or any other medical or uncontrolled autoimmune disorder(s) (example, diabetes mellitus) or clinically significant abnormalities in screening laboratory that, might interfere with the participants full participation in the study, or might jeopardize the safety of the participant or the validity of the study results
- Pure sensory CIDP or chronic immune sensory polyradiculopathy (CISP) (EAN/PNS definition)
- Any other disease that could better explain the participant's signs and symptoms, such as significant persisting neurological deficits from stroke or central nervous system (CNS) trauma or peripheral neuropathy from another cause such as connective tissue disease or systemic lupus erythematosus
- Polyneuropathy of other causes, including the following: Multifocal motor neuropathy (MMN); Monoclonal gammopathy of uncertain significance with antimyelin associated glycoprotein (anti-MAG) immunoglobulin M (IgM) antibodies; Hereditary motor neuropathy; Hereditary neuropathy with liability to pressure palsies (HNPP); Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes; Lumbosacral radiculoplexus neuropathy; Polyneuropathy most likely due to diabetes mellitus; Polyneuropathy most likely due to systemic illnesses; Drug- or toxin-induced polyneuropathy Note: A concomitant polyneuropathy of other causes (example, a mild, stable diabetic polyneuropathy) is not necessarily exclusionary if chronic inflammatory demyelinating polyneuropathy (CIDP) is confirmed as the main diagnosis, as determined by the investigator and confirmed by the adjudication committee
- Has known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients
- Other protocol-defined exclusion criteria will apply
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Nipocalimab
Participants in Stage A (Open-label) will receive a loading dose of nipocalimab (Dose 1) intravenous (IV) infusion on Day 1, followed by nipocalimab (Dose 2) IV infusion once every 2 weeks (q2w) from Week 2 to Week 12. Participants who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive nipocalimab (Dose 2) IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first. |
Nipocalimab will be administered intravenously.
Andre navne:
|
|
Placebo komparator: Placebo
Participants receiving nipocalimab in Stage A and who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive placebo IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first. |
Placebo will be administered intravenously. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Stage B: Time to First Occurrence of a Relapse Event
Tidsramme: Up to 52 weeks
|
Stage B time to first occurrence of a relapse event will be reported. |
Up to 52 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Stage A: Time to Initial Confirmed Evidence of Clinical Improvement (ECI)
Tidsramme: 12 weeks
|
Time to initial confirmed ECI will be reported. |
12 weeks
|
|
Stage A: Percentage of Responders as Determined by ECI
Tidsramme: 12 weeks
|
Stage A percentage of responders as determined by ECI will be reported. |
12 weeks
|
|
Stage A: Change from Baseline Over Time in Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale Score
Tidsramme: Baseline to 12 weeks
|
Change from Stage A baseline over time in adjusted INCAT disability scale score will be reported. The INCAT disability scale is a clinician-rated assessment that measures activity limitation and degree of functional disability. The INCAT scale is an ordinal scale scored from 0 to 10, with higher scores indicating more disability. |
Baseline to 12 weeks
|
|
Stage A: Change from Stage A Baseline Over Time in Medical Research Council (MRC) Muscle Grading Scale Sum Score
Tidsramme: Baseline to 12 weeks
|
Change from Stage A baseline over time in MRC muscle grading scale sum score will be reported. The MRC muscle grading scale is a clinician-rated outcome that provides a strength rating (on a scale from 0 [no visible contraction] to 5 [normal]) in 6 muscles collected bilaterally: deltoid, biceps, wrist extensors, iliopsoas, quadriceps, tibialis anterior. Lower scores indicate greater impairment. |
Baseline to 12 weeks
|
|
Stage A: Change from Baseline Over Time in Inflammatory Rasch-Built Overall Disability Scale (I-RODS) Centile Score
Tidsramme: Baseline to 12 weeks
|
Change from Stage A baseline over time in I-RODS centile score will be reported. The I-RODS comprises of 24 items representing common daily activities that address upper and lower limb disability and range in difficulty from very easy to very difficult. Lower scores indicate greater activity and social participation limitations. |
Baseline to 12 weeks
|
|
Stage A: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Tidsramme: Baseline to 12 weeks
|
Change from Stage A baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Baseline to 12 weeks
|
|
Stage A: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Tidsramme: Baseline to 12 weeks
|
Change from Stage A baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Baseline to 12 weeks
|
|
Stage B: Time to First Adjusted INCAT Disability Scale Score Deterioration Relative to Baseline
Tidsramme: Up to 52 weeks
|
Time to first adjusted INCAT disability scale score deterioration relative to Stage B baseline will be reported. |
Up to 52 weeks
|
|
Stage B: Time to First Switch to Intravenous Immunoglobulin (IVIg) or Other Standard of Care (SoC) as a Result of Investigator-assessed Lack of Efficacy as Confirmed by an Independent RAC Relative to Baseline
Tidsramme: Up to 52 weeks
|
Time to first switch to IVIg or other SoC as a result of investigator-assessed lack of efficacy as confirmed by an independent Relapse Adjudication Committee (RAC) relative to Stage B baseline will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in Adjusted INCAT Disability Score
Tidsramme: Up to 52 weeks
|
Change from Stage B baseline over time in adjusted INCAT disability score will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in MRC Muscle Grading Scale Sum Score
Tidsramme: Up to 52 weeks
|
Change from Stage B baseline over time in MRC Muscle Grading Scale Sum score will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in I-RODS Centile Score
Tidsramme: Up to 52 weeks
|
Change from Stage B baseline over time in I-RODS centile score will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Tidsramme: Up to 52 weeks
|
Change from Stage B baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Tidsramme: Up to 52 weeks
|
Change from Stage B baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Up to 52 weeks
|
|
Stage B: Number of Participants with Binary Response Endpoint Satisfying all 4 Conditions: a) An Improved Adjusted INCAT Disability Score Compared to Baseline; b) Not Relapsing; c) Not Switching to SoC; d) Not Discontinuing Treatment
Tidsramme: Up to 52 weeks
|
Number of participants with Binary response endpoint satisfying all 4 conditions: a) an improved adjusted INCAT Disability Score compared to Stage B baseline; b) not relapsing; c) not switching to SoC; d) not discontinuing treatment, will be reported. |
Up to 52 weeks
|
|
Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)
Tidsramme: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Percentage of Participants with Serious Adverse Events (SAEs)
Tidsramme: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Change in Electrocardiogram (ECG) Values Over Time
Tidsramme: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with change in ECG values over time will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Change in Vital Signs Values Over Time
Tidsramme: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with change in vital signs values over time will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Change in Clinical Laboratory Values Over Time
Tidsramme: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with change in clinical laboratory values over time will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Clinically Significant ECG Abnormalities
Tidsramme: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with clinically significant ECG abnormalities will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Clinically Significant Vital Signs Abnormalities
Tidsramme: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with clinically significant vital signs abnormalities will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Clinically Significant Clinical Laboratory Abnormalities
Tidsramme: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with clinically significant clinical laboratory abnormalities will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Percentage of Participants with Suicidal Ideation or Suicidal Behavior based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
Tidsramme: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Percentage of participants with suicidal ideation or suicidal behavior based on the C-SSRS will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Serum Nipocalimab Concentrations Over Time in Participants Receiving Active Study Intervention
Tidsramme: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Serum nipocalimab concentrations over time in participants receiving active study intervention will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Anti-drug Antibodies (ADA) to Nipocalimab
Tidsramme: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with ADA to Nipocalimab will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Titers of ADA to Nipocalimab
Tidsramme: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Titers of ADA to nipocalimab will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Neutralizing Antibodies (NAb) to Nipocalimab
Tidsramme: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with NAb to Nipocalimab will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Change from Baseline in Total Serum Immunoglobulin (IgG) Concentrations Levels Over Time
Tidsramme: Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks
|
Change from baseline in total serum IgG concentrations levels over time will be reported. |
Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks
|
Samarbejdspartnere og efterforskere
Efterforskere
- Studieleder: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i nervesystemet
- Patologiske processer
- Neuromuskulære sygdomme
- Kronisk sygdom
- Sygdomsegenskaber
- Autoimmune sygdomme
- Sygdomme i immunsystemet
- Sygdomme i det perifere nervesystem
- Autoimmune sygdomme i nervesystemet
- Demyeliniserende sygdomme
- Polyneuropatier
- Polyradiculoneuropati
- Patologiske tilstande, tegn og symptomer
- Polyradiculoneuropati, kronisk inflammatorisk demyeliniserende
Andre undersøgelses-id-numre
- CR109195
- 80202135CDP3001 (Anden identifikator: Janssen Research & Development, LLC)
- 2021-003234-37 (EudraCT nummer)
- 2023-508425-28-00 (Registry Identifier: EUCT number)
- 2023 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .